Drug Target Review: Could a nasal spray prevent COVID-19?

A UC study shows that a lipid might prevent infection and could potentially be easily administered

According to a study led by UC researchers, the lipid sphingosine may have the ability to inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.

Researchers, led by a visiting professor in the UC Department of Surgery Erich Gulbins, MD,  have examined pre-existing research into bacterial respiratory tract infections and applied the findings to COVID-19, with some success. According to the scientists, a sphingosine nasal spray could potentially prevent or treat SARS-CoV-2 infections.

“We investigated whether a specific lipid [sphingosine] is able to interfere with the binding of SARS-CoV-2 to human epithelial cells,” said Gulbins, corresponding author on the study, published in the Journal of Biological Chemistry. 

Read the full story.

Read the UC News release.

Featured photo of the lipid sphingosine courtesy of Jynto.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

3

UC researchers develop new CPAP device

April 17, 2024

Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.

Debug Query for this